Tocagen shares collapse as investigators read last rites for PhIII brain cancer study

San Diego Biotechnology Network
San Diego Biotechnology Network
Tocagen shares collapse as investigators read last rites for PhIII brain cancer study
Loading
/

Two years after going public on the promise of a new approach to fight recurrent brain cancer, Tocagen has hit the wall.

The biotech bluntly reported the failure of their pivotal Phase III study of a 2-part drug ? Toca 511 & Toca FC ?? for high-grade glioma. Part 1 uses a vector to attack cancer cells in the brain and deliver a gene for an enzyme, while part 2 is a prodrug ? 5-fluorocytosine (5-FC) ? that converts into the anti-cancer therapy 5-FU.

It didn?t work.?

Researchers at the San Diego-based biotech reported that they hit a hazard ratio of 1.06, reflecting an increased risk to patients, with a disastrous p-value of 0.6154. The company says it will now thoroughly analyze the data, but investors weren?t waiting around. The stock